Medtronic launches new AAA (abdominal aortic aneurysm) products:
This article was originally published in Clinica
Medtronic has CE-marked for sale in Europe a new delivery system for implanting its Talent stent graft system for treating abdominal aortic aneurysms (AAAs). The Xcelerant delivery device features several enhancements that provide physicians with greater control during an implant and can serve to reduce implant procedure times, says the company. It incorporates an improved catheter material, and an integrated deployment handle to enhance trackability, improve kink resistance and decrease deployment forces. Regarding another of the firm's AAA devices, which is available in the US, Medtronic has announced the availability of a new graft material - called Resilient - for its AneuRx stent graft. Resilient is a higher density graft material designed to reduce porosity and improve durability.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.